CryoPort Inc (NASDAQ:CYRX) – Equities research analysts at B. Riley raised their FY2021 earnings per share estimates for shares of CryoPort in a research note issued on Friday, July 19th. B. Riley analyst A. D’silva now forecasts that the consumer goods maker will post earnings per share of $0.25 for the year, up from their prior forecast of $0.24. B. Riley currently has a “Buy” rating and a $26.00 target price on the stock. B. Riley also issued estimates for CryoPort’s FY2022 earnings at $0.96 EPS.
A number of other research firms also recently commented on CYRX. Svb Leerink reiterated an “outperform” rating on shares of CryoPort in a research report on Monday, July 15th. BidaskClub upgraded Zebra Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, July 6th. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, July 1st. Finally, Leerink Swann started coverage on CryoPort in a research report on Monday, July 15th. They issued a “buy” rating and a $24.00 target price on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.00.
NASDAQ:CYRX opened at $19.45 on Monday. The company has a quick ratio of 11.52, a current ratio of 11.57 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $604.20 million, a P/E ratio of -62.74 and a beta of 0.85. CryoPort has a 12 month low of $8.28 and a 12 month high of $20.79. The stock has a 50-day moving average price of $18.64.
CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, May 2nd. The consumer goods maker reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). CryoPort had a negative return on equity of 28.30% and a negative net margin of 41.61%. The business had revenue of $6.65 million for the quarter, compared to the consensus estimate of $6.56 million. During the same period in the previous year, the business earned ($0.10) earnings per share. The business’s revenue was up 65.4% on a year-over-year basis.
Large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA purchased a new stake in shares of CryoPort in the first quarter worth about $74,000. Metropolitan Life Insurance Co. NY increased its stake in CryoPort by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock worth $95,000 after acquiring an additional 6,722 shares during the last quarter. MML Investors Services LLC bought a new stake in CryoPort during the fourth quarter worth approximately $157,000. Bank of America Corp DE increased its stake in CryoPort by 92.3% during the fourth quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock worth $176,000 after acquiring an additional 7,697 shares during the last quarter. Finally, Conestoga Capital Advisors LLC bought a new stake in CryoPort during the first quarter worth approximately $355,000. Institutional investors own 54.06% of the company’s stock.
CryoPort Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.